Cancer; Pathophysiology and Stress Modulation (Cancer, Therapeutic Interventions) von Scarpetti, Lauren, Guarino, Matthew, Baima, Jennifer

Volltext

The Shigella flexneri Type Three Secretion System Employs Both Chaperone‐Dependent and Noncanonical Chaperone‐Independent Pathways von Ramseyer, Julia, Ernst, Nadja, Scarpetti, Lauren, Lesser, Cammie

Volltext

Utility of ligamentum teres hepatis flap reinforcement to prevent postoperative pancreatic fistulas in robotic distal pancreatectomy von Scarpetti, Lauren, Bello, Ricardo J., Chung, Sebastian K., Hazeltine, Max D., Lindberg, James M.

Volltext

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53 von Scarpetti, Lauren, Oturkar, Chetan C, Juric, Dejan, Shellock, Maria, Malvarosa, Giuliana, Post, Kathryn, Isakoff, Steven, Wang, Nancy, Nahed, Brian, Oh, Kevin, Das, Gokul M, Bardia, Aditya

Volltext

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ER[beta] and Mutant p53 von Scarpetti, Lauren, Oturkar, Chetan C, Juric, Dejan, Shellock, Maria, Malvarosa, Giuliana, Post, Kathryn, Isakoff, Steven, Wang, Nancy, Nahed, Brian, Oh, Kevin, Das, Gokul M, Bardia, Aditya

Volltext

Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1) von Spring, Laura M, Scarpetti, Lauren, Niemierko, Andrzej, Isakoff, Steven J, Moy, Beverly, Wander, Seth A, Smith, Elisabeth, Abraham, Elizabeth, Shin, Jennifer, Patel, Jaymin M, Comander, Amy, Mulvey, Therese, Bardia, Aditya

Volltext

Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone... von Wander, Seth Andrew, Juric, Dejan, Supko, Jeffrey G., Micalizzi, Douglas Scott, Spring, Laura, Vidula, Neelima, Beeler, Maureen, Habin, Karleen R., Viscosi, Elene, Fitzgerald, Donna Michelle, Scarpetti, Lauren, Tripp, Elizabeth, Hepp, Rachel, Moy, Beverly, Isakoff, Steven J., Ellisen, Leif W., Bardia, Aditya

Volltext

Abstract OT2-08-01: A phase 1b trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy with/without CDK 4/6 inhibi... von Wander, Seth A., Juric, Dejan, Spring, Laura M., Vidula, Neelima, Beeler, Maureen, Habin, Karleen, Viscosi, Elene, Scarpetti, Lauren, Tripp, Elizabeth, Hepp, Rachel, Moy, Beverly, Isakoff, Steven J., Ellisen, Leif W., Bardia, Aditya

Volltext

Abstract PD17-03: Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib for localized HR+/HER2- breast cancer (LEADER) von Medford, Arielle J., Scarpetti, Lauren, Niemierko, Andrzej, Isakoff, Steven J., Moy, Beverly, Wander, Seth A., Deluca, Elizabeth, Abraham, Elizabeth, Shin, Jennifer, Schnipper, Lowell, Comander, Amy E., Mulvey, Therese, Spickard, Erik, Kalashnikova, Ekaterina, Rodriguez, Angel, Ellisen, Leif, Bardia, Aditya, Spring, Laura M.

Volltext